# FiscalAI

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/fiscalai-company
Canonical HTML page: https://getyourbrief.com/entity/fiscalai-company

## Timeline

- **2026-09-01**: Dividend payment — The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
- **2026-08-17**: Ex-dividend date — Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
- **2026-08-14**: Silexion reports quarterly results — Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-08-07**: EchoStar announces quarterly earnings — EchoStar reports EPS of $24.12, exceeding the consensus estimate of -$0.02 by $24.14. Revenue of $3.58 billion falls slightly short of the $3.59 billion estimate.
- **2026-07-31**: Baird price target and stock rebound — Robert W. Baird set a $66.00 price target; the stock traded up to $57.60, rising $1.79.
- **2026-07-30**: Q2 2026 earnings release — Middlesex Water reported Q2 EPS of $0.79 on revenue of $56.36 million; shares closed at $55.81, down $1.44.
- **2026-07-29**: Maxim Group downgrades to Hold — Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
- **2026-07-29**: Weiss Ratings upgrade — Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
- **2026-07-20**: Weiss Ratings downgrade — Weiss Ratings cut Middlesex Water from 'hold (c)' to 'hold (c-)'.
- **2026-07-17**: Weiss Ratings reiterates Sell — Restated a 'sell (e+)' rating on MBRX shares in a research note
- **2026-07-09**: New Street Research target — New Street Research set a $64.00 price target on Middlesex Water.
- **2026-06-15**: Weiss Ratings reiterates Sell (E+) — Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.
- **2026-06-05**: CEO Hamid Akhavan sold 52,586 shares — The sale was executed under a pre-arranged Rule 10b5-1 trading plan at $121.00 per share, totaling $6,362,906, reducing his ownership by 5.73%.

## Recent coverage (15 stories, network-wide)

### NBP & CRMZ Micro-Cap Earnings: $(0.16) vs $(0.04) EPS
2026-08-22 07:00:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
Full story: https://getfinancebrief.com/story/imab-creditriskmonitor-microcap-earnings-comparison

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Lantern Pharma Misses EPS by $0.19; AI Oncology Stock Sits 44% Below High
2026-08-16 16:15:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Full story: https://gethealthbrief.com/story/lantern-pharma-eps-miss-health-ai-oncology

### LTRN Misses EPS by $0.19 Yet Rises 0.8% to $2.65 on 2.3x Volume
2026-08-16 16:14:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Full story: https://getfinancebrief.com/story/ltrn-q2-earnings-miss-stock-reaction

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### SLXN Beats EPS by $16.03 Yet Trades at $0.42, Down 99.5% from High
2026-08-16 15:02:07 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion beat consensus by $16.03 with a ($5.17) EPS, yet shares fell to $0.42. With volume at 2x average, a 52-week high of $80, and Hold consensus, the microcap has shed nearly all value.
Full story: https://getfinancebrief.com/story/silexion-finance-earnings-microcap

### SLXN's RNAi Pipeline Faces $0.42 Stock and $5.17 EPS Loss
2026-08-16 15:01:58 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Full story: https://getbiobrief.com/story/silexion-rnai-pipeline-earnings

### Globant Misses EPS by $0.10; Revenue $614.4M, Stock Falls 8.9%
2026-08-16 11:39:33 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Full story: https://getfinancebrief.com/story/globant-q2-2026-earnings-miss-finance

### SENEA EPS miss overshadowed by 24% revenue beat; TALK misses both lines
2026-08-12 14:54:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seneca Foods posted a top-line beat of $405.17M, 24% above estimates, despite a $0.07 EPS miss, driving a 7.4% stock surge and Strong Buy ratings. Talkspace, meanwhile, missed on both EPS and revenue, but its stock held steady as institutional investors continued accumulating shares.
Full story: https://getfinancebrief.com/story/seneca-foods-talkspace-earnings-analysis-q2-2026

### United Maritime’s $0.12 EPS Beat Hints at Shipping Rate Recovery
2026-08-12 13:21:43 · Sector: supply · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Micro-cap dry bulk shipper United Maritime posted a $0.15 EPS, beating estimates by $0.12, on revenue of $9.99M. The beat, paired with a high dividend yield, may signal improving charter rates and tightening shipping capacity, offering critical insights for supply chain planners monitoring freight cost trends.
Full story: https://getsupplybrief.com/story/united-maritime-earnings-beat-shipping-logistics

### EFC Beat by $0.14, G & BCE Also Top: Dividend Yields Up to 11.5%
2026-08-09 00:19:08 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Ellington Financial, Genpact, and BCE all reported better-than-expected earnings this week. Reactions diverged: EFC rallied, while Genpact and BCE slipped. Income investors are drawn to yields as high as 11.5%, but analyst downgrades and cautious guidance warrant scrutiny.
Full story: https://getfinancebrief.com/story/earnings-beats-efc-g-bce-dividend-yields-2026

### EchoStar EPS Beats by $24.14, But Revenue Dips 4%—What’s Behind the Surge?
2026-08-08 14:14:29 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

EchoStar reported a massive $24.12 EPS versus expected -$0.02, topping estimates by $24.14. Revenue of $3.58B missed the mark slightly and fell 4% year-over-year. The divergence raises questions about earnings quality, while an insider stock sale by the CEO adds caution.
Full story: https://getfinancebrief.com/story/echostar-earnings-q2-2026-eps-beat-revenue-decline

### MSEX Q2 EPS Soars 27% to $0.79, Dividend Yield Holds at 2.5%
2026-08-01 00:15:30 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Middlesex Water's Q2 EPS of $0.79 surged past estimates, reinforcing its reputation as a stable income play. With a 2.5% yield and 60% payout ratio, the utility delivered strong net margins of 22.07%. However, mixed analyst ratings and a beta of 0.78 suggest cautious optimism.
Full story: https://getfinancebrief.com/story/middlesex-water-q2-earnings-beat-eps-dividend

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.